Yin Jiankang, Wang Hui, Zhu Gan, Chen Ni, Khan Muhammad Imran, Zhao Ye
School of Basic Medical Sciences, Anhui Medical University, Hefei, PR China.
Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, PR China.
Heliyon. 2023 Sep 1;9(9):e19749. doi: 10.1016/j.heliyon.2023.e19749. eCollection 2023 Sep.
This study aims to investigate the significance of interim whole-body dynamic F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) Patlak parameters for predicting the prognosis of patients with diffuse large B-cell lymphoma. To estimate the predictive value of the whole-body dynamic F-FDG PET/CT Patlak parameter for 2-year progression-free survival (PFS) and 2-year overall survival (OS).
This study reports the findings of 67 patients with diffuse large B-cell lymphoma (DLBCL). These patients underwent interim whole-body dynamic F-FDG PET/CT scans from June 2021 to January 2023 at the Department of Nuclear Medicine, First Affiliated Hospital of Anhui Medical University. The predictive values of maximum standard uptake value (SUV), maximum of net glucose uptake rate (Ki) and the predictive model combining Ki and interim treatment response on the prognosis of patients was analyzed using receiver operating characteristic (ROC) curves. Kaplan-Meier survival curves and log-rank tests were used for survival analysis. Univariate and multivariate analyses were performed to screen for independent prognostic risk factors.
After a median follow-up of 18 months, 21 patients (31.3%) experienced disease recurrence or death. The cut-off values for the SUV and the Ki were 6.1 and 0.13 μmol min·ml, respectively. Ann Arbor stage, IPI, SUV, Ki and interim treatment response were associated with PFS and OS in the univariate analysis. However, only Ki and interim treatment response were independent influences on PFS and OS in multivariate analysis.
Interim whole-body dynamic F-FDG PET/CT Patlak imaging has significant prognostic value in patients with DLBCL. Among them, the interim dynamic parameter Ki showed the best predictive value for prognosis compared with the interim SUV and interim treatment response. The predictive model established by Ki and the interim treatment response allowed for the accurate stratification of the prognostic risk of DLBCL.
本研究旨在探讨中期全身动态氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）Patlak参数对弥漫性大B细胞淋巴瘤患者预后的预测意义。评估全身动态F-FDG PET/CT Patlak参数对2年无进展生存期（PFS）和2年总生存期（OS）的预测价值。
本研究报告了67例弥漫性大B细胞淋巴瘤（DLBCL）患者的研究结果。这些患者于2021年6月至2023年1月在安徽医科大学第一附属医院核医学科接受了中期全身动态F-FDG PET/CT扫描。使用受试者工作特征（ROC）曲线分析最大标准摄取值（SUV）、最大净葡萄糖摄取率（Ki）以及结合Ki和中期治疗反应的预测模型对患者预后的预测价值。采用Kaplan-Meier生存曲线和对数秩检验进行生存分析。进行单因素和多因素分析以筛选独立的预后危险因素。
中位随访18个月后，21例患者（31.3%）出现疾病复发或死亡。SUV和Ki的截断值分别为6.1和0.13μmol·min·ml。单因素分析中，Ann Arbor分期、国际预后指数（IPI）、SUV、Ki和中期治疗反应与PFS和OS相关。然而，多因素分析中只有Ki和中期治疗反应对PFS和OS有独立影响。
中期全身动态F-FDG PET/CT Patlak成像对DLBCL患者具有显著的预后价值。其中，与中期SUV和中期治疗反应相比，中期动态参数Ki对预后的预测价值最佳。由Ki和中期治疗反应建立的预测模型能够准确分层DLBCL的预后风险。
Zotero 插件